Axitinib is also being investigated in a randomized Phase 3 clinical trial in patients with treatment-naïve as well as previously treated advanced RCC, and in a randomized Phase 2 clinical trial for the treatment of hepatocellular carcinoma (HCC).
About SFJ Pharmaceuticals, Inc.
The SFJ Pharmaceuticals Group, which was formed in January of 2009, and includes SFJ Pharma Ltd. II, is a Global Drug Development Company, which provides a unique co-development partnering model for some of the world's top Pharmaceutical and Biotechnology companies. SFJ uses its financial strength and core team of pharmaceutical development experts to provide highly customized partnering models in which SFJ provides the funding and clinical development supervision, necessary to obtain regulatory approval for some of the most promising drug development programs of Pharmaceutical and Biotechnology companies. SFJ is backed by Abingworth, Clarus and Fintech, which are venture capital firms specializing in bio-pharmaceutical development. Collectively these venture capital firms manage over USD $2.5 billion in funding.
|SOURCE SFJ Pharma|
Copyright©2010 PR Newswire.
All rights reserved